Daniel Pastula
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Zika Virus Infection | 9 | 2018 | 85 | 2.410 |
Why?
| Encephalitis, California | 4 | 2019 | 11 | 1.970 |
Why?
| Epilepsy | 6 | 2023 | 291 | 1.630 |
Why?
| Guillain-Barre Syndrome | 5 | 2017 | 21 | 1.610 |
Why?
| Encephalitis, Tick-Borne | 3 | 2023 | 8 | 1.510 |
Why?
| Flavivirus Infections | 2 | 2019 | 9 | 1.460 |
Why?
| Disease Outbreaks | 8 | 2023 | 333 | 1.450 |
Why?
| Sexual and Gender Minorities | 2 | 2022 | 139 | 1.450 |
Why?
| Amyotrophic Lateral Sclerosis | 6 | 2015 | 68 | 1.440 |
Why?
| Bunyaviridae Infections | 3 | 2019 | 6 | 1.380 |
Why?
| Central Nervous System Diseases | 2 | 2023 | 64 | 1.370 |
Why?
| Monkeypox virus | 3 | 2023 | 12 | 1.330 |
Why?
| Nervous System Diseases | 4 | 2023 | 265 | 1.190 |
Why?
| Chikungunya Fever | 2 | 2017 | 63 | 1.080 |
Why?
| Meningitis | 2 | 2023 | 74 | 1.070 |
Why?
| Encephalitis | 3 | 2023 | 128 | 1.040 |
Why?
| Medical Tourism | 1 | 2023 | 10 | 0.940 |
Why?
| Arbovirus Infections | 2 | 2023 | 17 | 0.930 |
Why?
| Smallpox Vaccine | 1 | 2023 | 24 | 0.920 |
Why?
| Flavivirus | 2 | 2019 | 16 | 0.910 |
Why?
| Optic Neuritis | 1 | 2023 | 37 | 0.890 |
Why?
| Encephalomyelitis | 1 | 2022 | 9 | 0.890 |
Why?
| Encephalitis Virus, California | 3 | 2019 | 6 | 0.860 |
Why?
| Phlebovirus | 3 | 2020 | 4 | 0.860 |
Why?
| Exanthema | 1 | 2022 | 78 | 0.830 |
Why?
| Mycobacterium abscessus | 1 | 2023 | 97 | 0.820 |
Why?
| Creatine | 2 | 2012 | 56 | 0.810 |
Why?
| Neuroprotective Agents | 2 | 2012 | 110 | 0.770 |
Why?
| Acyclovir | 1 | 2020 | 104 | 0.730 |
Why?
| Encephalomyelitis, Eastern Equine | 1 | 2019 | 6 | 0.720 |
Why?
| Neurology | 2 | 2019 | 95 | 0.710 |
Why?
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 28 | 0.700 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2023 | 334 | 0.650 |
Why?
| Thrombocytopenia | 2 | 2017 | 188 | 0.650 |
Why?
| Hepatitis E | 1 | 2017 | 2 | 0.600 |
Why?
| Hepatitis E virus | 1 | 2017 | 2 | 0.600 |
Why?
| Myelitis | 4 | 2021 | 87 | 0.600 |
Why?
| Epidemiological Monitoring | 1 | 2017 | 50 | 0.600 |
Why?
| Dengue | 1 | 2016 | 60 | 0.550 |
Why?
| Communicable Diseases, Emerging | 1 | 2016 | 28 | 0.550 |
Why?
| Antiviral Agents | 1 | 2020 | 670 | 0.500 |
Why?
| Ixodidae | 1 | 2014 | 7 | 0.490 |
Why?
| Humans | 49 | 2023 | 122796 | 0.490 |
Why?
| Zika Virus | 5 | 2018 | 61 | 0.490 |
Why?
| Critical Care | 1 | 2017 | 563 | 0.430 |
Why?
| Enterovirus Infections | 3 | 2021 | 165 | 0.400 |
Why?
| Homosexuality, Male | 2 | 2022 | 176 | 0.390 |
Why?
| Meningoencephalitis | 2 | 2021 | 24 | 0.380 |
Why?
| Male | 24 | 2023 | 59639 | 0.320 |
Why?
| Infant | 9 | 2022 | 8523 | 0.320 |
Why?
| Muscle Hypotonia | 2 | 2018 | 29 | 0.310 |
Why?
| Fatal Outcome | 4 | 2018 | 299 | 0.310 |
Why?
| United States | 10 | 2023 | 13272 | 0.300 |
Why?
| Population Surveillance | 4 | 2018 | 439 | 0.300 |
Why?
| North America | 2 | 2019 | 271 | 0.300 |
Why?
| Motor Neuron Disease | 3 | 2012 | 17 | 0.290 |
Why?
| Child, Preschool | 8 | 2022 | 9755 | 0.290 |
Why?
| Culicidae | 2 | 2016 | 29 | 0.270 |
Why?
| Enterovirus D, Human | 2 | 2016 | 76 | 0.260 |
Why?
| Animals | 11 | 2023 | 34133 | 0.250 |
Why?
| Infant, Newborn | 4 | 2022 | 5430 | 0.250 |
Why?
| Child | 10 | 2022 | 19561 | 0.240 |
Why?
| Glial Fibrillary Acidic Protein | 2 | 2023 | 86 | 0.240 |
Why?
| Rituximab | 2 | 2023 | 161 | 0.240 |
Why?
| Autoimmune Diseases of the Nervous System | 1 | 2023 | 19 | 0.240 |
Why?
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 44 | 0.230 |
Why?
| Middle Aged | 11 | 2020 | 28563 | 0.220 |
Why?
| District of Columbia | 1 | 2022 | 28 | 0.220 |
Why?
| Encephalitis, Viral | 1 | 2023 | 44 | 0.220 |
Why?
| West Nile Fever | 1 | 2023 | 52 | 0.220 |
Why?
| Adolescent | 10 | 2023 | 18948 | 0.220 |
Why?
| Enterovirus A, Human | 1 | 2021 | 12 | 0.200 |
Why?
| Age of Onset | 2 | 2015 | 479 | 0.200 |
Why?
| Registries | 1 | 2009 | 2020 | 0.200 |
Why?
| Acute Disease | 4 | 2018 | 984 | 0.200 |
Why?
| Adult | 11 | 2023 | 32385 | 0.190 |
Why?
| Vital Capacity | 2 | 2012 | 277 | 0.190 |
Why?
| Disease Progression | 4 | 2012 | 2546 | 0.190 |
Why?
| Colorado | 3 | 2022 | 4325 | 0.190 |
Why?
| Central Nervous System Viral Diseases | 1 | 2021 | 62 | 0.190 |
Why?
| Young Adult | 6 | 2023 | 11094 | 0.190 |
Why?
| Hashimoto Disease | 1 | 2020 | 9 | 0.190 |
Why?
| Simplexvirus | 1 | 2020 | 85 | 0.180 |
Why?
| Incidence | 5 | 2018 | 2527 | 0.180 |
Why?
| Bunyamwera virus | 1 | 2019 | 3 | 0.180 |
Why?
| Neuromuscular Diseases | 1 | 2021 | 89 | 0.180 |
Why?
| Interferon-gamma | 1 | 2023 | 747 | 0.180 |
Why?
| Administration, Intravenous | 1 | 2020 | 152 | 0.180 |
Why?
| Immunologic Factors | 1 | 2021 | 228 | 0.170 |
Why?
| Seizures | 1 | 2022 | 360 | 0.170 |
Why?
| Central Nervous System Infections | 1 | 2019 | 38 | 0.170 |
Why?
| Immunoglobulin G | 1 | 2023 | 804 | 0.170 |
Why?
| Autopsy | 2 | 2015 | 89 | 0.170 |
Why?
| Veterans | 1 | 2009 | 1203 | 0.170 |
Why?
| Aged | 9 | 2018 | 20495 | 0.170 |
Why?
| Stem Cells | 1 | 2023 | 576 | 0.170 |
Why?
| La Crosse virus | 1 | 2017 | 6 | 0.160 |
Why?
| Magnetic Resonance Imaging | 2 | 2023 | 3264 | 0.160 |
Why?
| Motor Disorders | 1 | 2018 | 18 | 0.160 |
Why?
| Skin | 1 | 2022 | 694 | 0.150 |
Why?
| Micronesia | 1 | 2017 | 3 | 0.150 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2012 | 1260 | 0.150 |
Why?
| Fever | 2 | 2017 | 289 | 0.150 |
Why?
| Encephalomyelitis, Equine | 1 | 2016 | 1 | 0.150 |
Why?
| Encephalitis Virus, Eastern Equine | 1 | 2016 | 2 | 0.150 |
Why?
| Pandemics | 2 | 2023 | 1401 | 0.150 |
Why?
| International Classification of Diseases | 1 | 2017 | 128 | 0.150 |
Why?
| Fiji | 1 | 2016 | 3 | 0.150 |
Why?
| Female | 15 | 2021 | 63629 | 0.150 |
Why?
| Diagnostic Errors | 1 | 2017 | 171 | 0.140 |
Why?
| Health Surveys | 1 | 2018 | 468 | 0.140 |
Why?
| Antibodies, Viral | 4 | 2023 | 551 | 0.140 |
Why?
| Arthropod Vectors | 1 | 2016 | 7 | 0.140 |
Why?
| Ticks | 1 | 2016 | 12 | 0.140 |
Why?
| Encephalitis Viruses, Tick-Borne | 1 | 2016 | 7 | 0.140 |
Why?
| Neurologic Examination | 1 | 2016 | 127 | 0.140 |
Why?
| Aged, 80 and over | 3 | 2017 | 6845 | 0.140 |
Why?
| Thogotovirus | 1 | 2015 | 1 | 0.130 |
Why?
| Lyme Disease | 1 | 2015 | 32 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2023 | 1814 | 0.130 |
Why?
| Chikungunya virus | 1 | 2016 | 64 | 0.130 |
Why?
| Health Services Needs and Demand | 1 | 2017 | 265 | 0.130 |
Why?
| Pregnancy Complications, Infectious | 1 | 2018 | 301 | 0.120 |
Why?
| Quality of Life | 2 | 2022 | 2457 | 0.120 |
Why?
| Plant Oils | 1 | 2013 | 28 | 0.120 |
Why?
| Cluster Analysis | 1 | 2014 | 493 | 0.110 |
Why?
| Puerto Rico | 3 | 2017 | 53 | 0.110 |
Why?
| Models, Statistical | 1 | 2017 | 651 | 0.110 |
Why?
| Curriculum | 1 | 2019 | 925 | 0.110 |
Why?
| Linear Models | 1 | 2015 | 854 | 0.110 |
Why?
| Age Factors | 2 | 2018 | 3114 | 0.110 |
Why?
| Case-Control Studies | 2 | 2016 | 3296 | 0.100 |
Why?
| Biopsy | 1 | 2015 | 1090 | 0.100 |
Why?
| Parkinson Disease | 1 | 2015 | 346 | 0.100 |
Why?
| Emergency Service, Hospital | 1 | 2022 | 1922 | 0.100 |
Why?
| Hospitalization | 2 | 2017 | 1914 | 0.100 |
Why?
| Health Promotion | 1 | 2017 | 707 | 0.100 |
Why?
| Multiple Sclerosis | 1 | 2015 | 395 | 0.090 |
Why?
| Vietnam | 1 | 2009 | 23 | 0.090 |
Why?
| Alzheimer Disease | 1 | 2015 | 513 | 0.090 |
Why?
| Muscle Cramp | 1 | 2009 | 8 | 0.090 |
Why?
| Piracetam | 1 | 2009 | 16 | 0.090 |
Why?
| Dietary Supplements | 1 | 2013 | 473 | 0.090 |
Why?
| Influenza, Human | 1 | 2015 | 566 | 0.090 |
Why?
| Muscle Spasticity | 1 | 2009 | 54 | 0.080 |
Why?
| Anticonvulsants | 1 | 2009 | 189 | 0.080 |
Why?
| Kaplan-Meier Estimate | 1 | 2009 | 884 | 0.070 |
Why?
| Proportional Hazards Models | 1 | 2009 | 1184 | 0.070 |
Why?
| United States Department of Veterans Affairs | 1 | 2009 | 564 | 0.070 |
Why?
| Brain | 1 | 2017 | 2540 | 0.060 |
Why?
| Survival Rate | 1 | 2009 | 1810 | 0.060 |
Why?
| Clinical Trials as Topic | 1 | 2008 | 985 | 0.060 |
Why?
| Astrocytes | 1 | 2023 | 176 | 0.050 |
Why?
| Eosinophils | 1 | 2023 | 273 | 0.050 |
Why?
| Cross Reactions | 1 | 2020 | 118 | 0.050 |
Why?
| Microspheres | 1 | 2020 | 132 | 0.050 |
Why?
| Immunoassay | 1 | 2020 | 101 | 0.050 |
Why?
| Antigens, Viral | 1 | 2020 | 181 | 0.050 |
Why?
| Immunoglobulin M | 1 | 2020 | 288 | 0.040 |
Why?
| Delphi Technique | 1 | 2019 | 170 | 0.040 |
Why?
| Missouri | 1 | 2018 | 65 | 0.040 |
Why?
| Epilepsia Partialis Continua | 1 | 2017 | 3 | 0.040 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2020 | 159 | 0.040 |
Why?
| Epilepsy, Generalized | 1 | 2017 | 14 | 0.040 |
Why?
| Epilepsies, Partial | 1 | 2017 | 28 | 0.040 |
Why?
| Ohio | 1 | 2017 | 144 | 0.040 |
Why?
| Paraplegia | 1 | 2017 | 63 | 0.040 |
Why?
| Insurance, Major Medical | 1 | 2017 | 2 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2023 | 936 | 0.040 |
Why?
| Microcephaly | 1 | 2018 | 56 | 0.040 |
Why?
| Arkansas | 1 | 2016 | 15 | 0.040 |
Why?
| Muscle Weakness | 1 | 2017 | 83 | 0.040 |
Why?
| Serogroup | 1 | 2016 | 32 | 0.040 |
Why?
| Medical Records | 1 | 2017 | 181 | 0.040 |
Why?
| Serologic Tests | 1 | 2016 | 56 | 0.040 |
Why?
| Headache | 1 | 2017 | 134 | 0.040 |
Why?
| Long-Term Care | 1 | 2017 | 73 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2017 | 149 | 0.040 |
Why?
| Immunocompromised Host | 1 | 2018 | 205 | 0.040 |
Why?
| Self-Management | 1 | 2018 | 136 | 0.040 |
Why?
| Public Health Surveillance | 1 | 2016 | 63 | 0.030 |
Why?
| Spasms, Infantile | 1 | 2017 | 103 | 0.030 |
Why?
| Autoantibodies | 1 | 2023 | 1353 | 0.030 |
Why?
| Geographic Mapping | 1 | 2015 | 23 | 0.030 |
Why?
| Electroencephalography | 1 | 2017 | 408 | 0.030 |
Why?
| Kansas | 1 | 2015 | 30 | 0.030 |
Why?
| Immunoglobulins, Intravenous | 1 | 2016 | 130 | 0.030 |
Why?
| Pregnancy | 2 | 2018 | 5854 | 0.030 |
Why?
| Forecasting | 1 | 2017 | 372 | 0.030 |
Why?
| Vaccination | 1 | 2023 | 1241 | 0.030 |
Why?
| Genome, Viral | 1 | 2015 | 125 | 0.030 |
Why?
| Neurodegenerative Diseases | 1 | 2015 | 98 | 0.030 |
Why?
| Coconut Oil | 1 | 2013 | 2 | 0.030 |
Why?
| Public Health | 1 | 2018 | 480 | 0.030 |
Why?
| Nutrition Therapy | 1 | 2013 | 33 | 0.030 |
Why?
| Clinical Competence | 1 | 2019 | 973 | 0.030 |
Why?
| Prevalence | 1 | 2018 | 2442 | 0.030 |
Why?
| Databases, Factual | 1 | 2017 | 1287 | 0.030 |
Why?
| RNA, Viral | 1 | 2015 | 597 | 0.030 |
Why?
| Phylogeny | 1 | 2015 | 830 | 0.020 |
Why?
| Placebos | 1 | 2009 | 204 | 0.020 |
Why?
| Treatment Outcome | 2 | 2016 | 9692 | 0.020 |
Why?
| Review Literature as Topic | 1 | 2008 | 82 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2016 | 1562 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 2500 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2018 | 4882 | 0.020 |
Why?
| Biomarkers | 1 | 2016 | 3662 | 0.020 |
Why?
| Data Collection | 1 | 2008 | 667 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 6682 | 0.020 |
Why?
| Pilot Projects | 1 | 2009 | 1477 | 0.020 |
Why?
| Risk Factors | 1 | 2018 | 9381 | 0.020 |
Why?
| Research Design | 1 | 2008 | 1002 | 0.010 |
Why?
| Biomedical Research | 1 | 2008 | 630 | 0.010 |
Why?
| Retrospective Studies | 1 | 2016 | 13433 | 0.010 |
Why?
|
|
Pastula's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|